A Safety Monitoring Procedure for a Clinical Drug Development Program, with Application to the Assessment of a Novel COX-2 Inhibitor
Kim Bolland(University of Reading), Mary Oldham(GlaxoSmithKline (United Kingdom)), John Whitehead(Lancaster City Council)
Cited by 0
Related Papers
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
A general parametric approach to the meta‐analysis of randomized clinical trials
|Statistics in Medicine|1991|765
The Design and Analysis of Sequential Clinical Trials.
|Journal of the American Statistical Association|1985|638
The Design and Analysis of Sequential Clinical Trials.
|Biometrics|1997|523